AstraZeneca is paying Innate Pharma at least $242M in near-term cash to sew up rights to monalizumab-plus
Just 2 days after rolling out a positive snapshot of activity for its NKG2A immune checkpoint inhibitor monalizumab at ESMO, Innate Pharma SA (Euronext: $IPH) has struck a rich add-on collaboration deal with AstraZeneca, which is bulking up its I/O pipeline in a deal that includes $170 million in upfront payments, a $72 million equity deal plus billions in added milestone payments covering a range of development programs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.